Enliven sticks to year-end ENABLE-2 start after FDA alignment on CML trial design
Enliven Therapeutics said it remains on track to begin the Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026, with $884.4 million in cash to fund operations into 2030.
FDA, SEC filing (2)